Lukang Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for lenvatinib mesylate capsules issued by the State Drug Administration. The specification is 4 mg, and the registration classification is 4 categories of chemicals. This drug is suitable for patients with unresectable hepatocellular carcinoma who have not previously received systemic treatment. Currently, 18 domestic companies have been approved for generic drugs according to the new registration classification. Domestic sales for the first quarter of 2025 and 2026 were 649 million yuan and 419 million yuan respectively. The company invested about 8.59 million yuan in R&D. The drug has been approved to enrich the company's formulation pipeline, but there is uncertainty about sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.